Equity Profile

CGON

CG Oncology, Inc.

Health CareBiotechnology$5.5B

Aug7Fri

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth demonstrates the company's ability to expand its market presence and is crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative cancer therapies. With a market cap of $5 billion, it operates in the health care sector, which is increasingly important as the demand for effective cancer treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In Q1-2026, CG Oncology reported an EPS of -$0.71, missing estimates by 23.26%. The stock saw a slight increase of 0.64% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially given the company's recent history of missing EPS estimates. The lack of analyst estimates adds to the uncertainty.

Bull Case

If CG Oncology can show improved revenue and a smaller EPS loss, it may signal progress in its drug development pipeline, boosting investor confidence.

Bear Case

Continued losses and missed expectations could lead to a significant drop in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's recent history of missing EPS estimates, this number will be critical in shaping investor sentiment.

What updates can management provide on revenue growth and product development?

Investors will be looking for signs of progress in the company's drug pipeline, which could influence future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about CG Oncology's revenue potential, given the recent focus on cancer therapies and the company's innovative pipeline.

Supporting Evidence

The high implied volatility suggests that the market is bracing for significant news, which could be positive if the company has made progress.

Insider selling could indicate confidence in the company's long-term strategy, despite short-term losses.

Key Risk

If the EPS comes in better than expected, it could shift the narrative around the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved financial performance against the backdrop of previous losses and missed expectations.

Bull Confirmed If

An EPS loss of less than $0.50 would indicate improved financial health and could lead to a positive market reaction.

Bear Confirmed If

An EPS loss greater than $0.75 would confirm ongoing challenges and likely lead to a negative market response.

Pre-Earnings Positioning

Options Market

Implied Move

±40.56%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect substantial volatility around the earnings report.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 15 of 29 (52%)

This setup has occurred 30 times across Health Care in the last 2 years. 15 of 29 faded and 14 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.9%, with a raw directional average of -1.9% (modestly negative historical bias).

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.1M

15,600 sh

1 insider

Net

$1.1M

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests the stock could rise by around 0.10% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

If the company misses expectations, history indicates an average decline of 0.79% on the first day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of drug trials and their expected timelines.
2Management's commentary on revenue projections for the upcoming quarters.
3Insights into operational efficiencies that could reduce costs.
4Details on partnerships or collaborations that may enhance product development.
5Responses to questions about competitive positioning in the oncology market.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

BP p.l.c.

Company Snapshot

CG Oncology, Inc. is a biotechnology company focused on developing innovative cancer therapies....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors will closely monitor.

N/A

Revenue Growth

Revenue growth demonstrates the company's ability to expand its market presence and is crucial for investor confidence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

CGON Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-28.85%

Avg Stock Reaction

+0.62%

Last Quarter Recap

In Q1-2026, CG Oncology reported an EPS of -$0.71, missing estimates by 23.26%. The stock saw a slight increase of 0.64% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautious ahead of the earnings report, especially given the company's recent history of missing EPS estimates. The lack of analyst estimates adds to the uncertainty.

Bull Case

If CG Oncology can show improved revenue and a smaller EPS loss, it may signal progress in its drug development pipeline, boosting investor confidence.

Bear Case

Continued losses and missed expectations could lead to a significant drop in stock price, especially given the high implied volatility in the options market.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to previous quarters?

Given the company's recent history of missing EPS estimates, this number will be critical in shaping investor sentiment.

What updates can management provide on revenue growth and product development?

Investors will be looking for signs of progress in the company's drug pipeline, which could influence future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly pessimistic about CG Oncology's revenue potential, given the recent focus on cancer therapies and the company's innovative pipeline.

Supporting Evidence

The high implied volatility suggests that the market is bracing for significant news, which could be positive if the company has made progress.

Insider selling could indicate confidence in the company's long-term strategy, despite short-term losses.

Key Risk

If the EPS comes in better than expected, it could shift the narrative around the company's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for improved financial performance against the backdrop of previous losses and missed expectations.

Bull Confirmed If

An EPS loss of less than $0.50 would indicate improved financial health and could lead to a positive market reaction.

Bear Confirmed If

An EPS loss greater than $0.75 would confirm ongoing challenges and likely lead to a negative market response.

Pre-Earnings Positioning

Options Market

Implied Move

±40.56%

Historical Avg

±5.2%

Pricing rich

The options market is pricing in a significant potential move, indicating that investors expect substantial volatility around the earnings report.

Options are pricing ±37.0% while CGON has averaged ±5.2% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

51.9%

Calls (12K)P/C Ratio: 2.80Puts (100)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 15 of 29 (52%)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$1.1M

15,600 sh

1 insider

Net

$1.1M

Net selling

Most Active Insiders· 1 open-market trade

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If CG Oncology beats expectations, history suggests the stock could rise by around 0.10% on the first day, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further guidance from management.

Miss

If the company misses expectations, history indicates an average decline of 0.79% on the first day, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the status of drug trials and their expected timelines.
2Management's commentary on revenue projections for the upcoming quarters.
3Insights into operational efficiencies that could reduce costs.
4Details on partnerships or collaborations that may enhance product development.
5Responses to questions about competitive positioning in the oncology market.